{
    "organizations": [],
    "uuid": "27675f0847dcad6639fad420a53e35a9266ade55",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-retrophin-initiates-pivotal-phase/brief-retrophin-initiates-pivotal-phase-3-clinical-trial-of-sparsentan-for-the-treatment-of-focal-segmental-glomerulosclerosis-idUSASC09UOG",
    "ord_in_thread": 0,
    "title": "BRIEF-Retrophin Initiates Pivotal Phase 3 Clinical Trial Of Sparsentan For The Treatment Of Focal Segmental Glomerulosclerosis",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 3 (Reuters) - Retrophin Inc:\n* RETROPHIN INITIATES PIVOTAL PHASE 3 CLINICAL TRIAL OF SPARSENTAN FOR THE TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-03T20:11:00.000+03:00",
    "crawled": "2018-04-04T12:40:12.002+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "retrophin",
        "inc",
        "retrophin",
        "initiate",
        "pivotal",
        "phase",
        "clinical",
        "trial",
        "sparsentan",
        "treatment",
        "focal",
        "segmental",
        "glomerulosclerosis",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}